Relmada Picks Bladder-Cancer Drug Development Chief To Lead Its Planned Late-Stage Trial Push

The new chief led ADSTILADRIN's pivotal program, while Relmada targets a year-end submission for its own bladder-cancer candidate.

Share
Relmada Picks Bladder-Cancer Drug Development Chief To Lead Its Planned Late-Stage Trial Push

Relmada Therapeutics, which develops experimental medicines for bladder cancer and neurological disorders, appointed a development chief Monday to lead clinical work across its pipeline, including a planned late-stage bladder-cancer program. The company named board-certified urologist Jørn Skibsted Jakobsen chief development officer for urology and uro-oncology, according to its SEC filing.

An ADSTILADRIN Veteran Takes Charge

Jakobsen led the pivotal development of Ferring Pharmaceuticals' ADSTILADRIN, a bladder-cancer treatment that won approvals in the United States, Europe, Japan and Canada, Relmada said in its appointment announcement.

His nine years at Ferring included responsibility for urology and uro-oncology, clinical strategy and work with regulators. He also broadened ADSTILADRIN's studies to additional patient groups, including research supporting potential expansion of its approved uses.

Jakobsen brings more than 25 years in patient care, research and drug development. Before Ferring, he treated bladder and prostate cancer as chief urologist at Herlev University Hospital in Denmark and worked as a consultant urologist at Odense University Hospital.

Durable Responses, And Disease Progression

Relmada's lead candidate, NDV-01, delivers a controlled-release combination of gemcitabine and docetaxel into the bladder to treat cancer that has not invaded the bladder muscle. The treatment is in a mid-stage trial; Relmada has no approved products and has generated no revenue.

In Thursday's business update, 12 of 14 evaluable patients with a complete response at 12 months still had that response at 18 months. Two patients who had not previously received BCG treatment progressed to muscle-invasive disease at the 15-month assessment.

Jakobsen said the candidate could suit everyday urology care through “convenient in-office administration with a ready-to-use product” in the appointment announcement.

Relmada also develops sepranolone for Prader-Willi syndrome, Tourette syndrome and essential tremor. Its worldwide rights to NDV-01 exclude Israel, India and South Africa.

Cash For The SPECTRUM Plan

Relmada held approximately $202.1 million in cash, cash equivalents and short-term investments at September 30. Management expects those resources to cover operations through 2029 and has established a manufacturing plan to supply the planned late-stage program through completion.

The company targets a submission by year-end 2026 seeking permission to begin clinical trials. Its planned SPECTRUM program is intended to support approval of NDV-01.

Relmada plans to start SPECTRUM after clearance of that submission.

Sources

More on Relmada Therapeutics

All Relmada Therapeutics (RLMD) coverage →